Literature DB >> 29232486

An Essential Warning.

Benjamin Z Leder1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29232486     DOI： 10.1002/jbmr.3359

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN： 0884-0431            Impact factor:   6.741


× No keyword cloud information.
  7 in total

1.  Warning of an increased risk of vertebral fracture after stopping denosumab.

Authors:  Christopher Symonds; Gregory Kline
Journal:  CMAJ       Date:  2018-04-23       Impact factor: 8.262

2.  Vertebral Fractures After Denosumab Discontinuation in Breast Cancer Survivors: A Single Institution Experience.

Authors:  Michele Yeung; Kaylee Ho; Monica N Fornier; Azeez Farooki
Journal:  HSS J       Date:  2021-03-04

3.  Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.

Authors:  Elizabeth Shane; Stephanie Shiau; Robert R Recker; Joan M Lappe; Sanchita Agarwal; Mafo Kamanda-Kosseh; Mariana Bucovsky; Julie Stubby; Adi Cohen
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 6.134

Review 4.  Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer.

Authors:  Pamela Taxel; Erika Faircloth; Sana Idrees; Catherine Van Poznak
Journal:  J Endocr Soc       Date:  2018-05-21

Review 5.  Should denosumab treatment for osteoporosis be continued indefinitely?

Authors:  Jane A Noble; Malachi J McKenna; Rachel K Crowley
Journal:  Ther Adv Endocrinol Metab       Date:  2021-04-22       Impact factor: 3.565

Review 6.  Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy.

Authors:  Benjamin Z Leder
Journal:  JBMR Plus       Date:  2018-02-27

7.  Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial.

Authors:  Adi Cohen; Stephanie Shiau; Nandini Nair; Robert R Recker; Joan M Lappe; David W Dempster; Thomas L Nickolas; Hua Zhou; Sanchita Agarwal; Mafo Kamanda-Kosseh; Mariana Bucovsky; John M Williams; Donald J McMahon; Julie Stubby; Elizabeth Shane
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.